Last updated on July 2019

CINC424A2X01B Rollover Protocol


Brief description of study

This roll-over protocol allows patients who are still receiving clinical benefit to continue to be treated from multiple protocols in one program spanning multiple indications during the completion of the parent study/(ies). The population for the roll-over study should be consistent with the population defined in the program parent study/(ies). The primary eligibility criteria for a patient to enter the roll-over protocol is the participation and completion of a Novartis OGD&GMA/Incyte study with ruxolitinib. Efficacy parameters would not be measured; however safety data will be collected.

Patients who have completed a prior study with ruxolitinib and who are assessed by the Investigator to continue to benefit from ongoing treatment with the investigational ruxolitinib will be eligible.

Clinical Study Identifier: NCT02386800

Find a site near you

Start Over

Novartis Investigative Site

Seoul, Korea, Republic of
  Connect »

Novartis Investigative Site

Moscow, Russian Federation
  Connect »

Novartis Investigative Site

Petrozavodsk, Russian Federation
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.